Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Argenx Profits Jump as Vyvgart Sales Beat Forecasts

Summary by belganewsagency.eu
Belgian-Dutch biotech firm Argenx nearly tripled its quarterly operating profit after strong sales of its rare disease treatment Vyvgart.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

belganewsagency.eubelganewsagency.eu

Argenx profits jump as Vyvgart sales beat forecasts

Belgian-Dutch biotech firm Argenx nearly tripled its quarterly operating profit after strong sales of its rare disease treatment Vyvgart.

Read Full Article
De TijdDe Tijd

Biotech Company Argenx Meets Forecast, Star Drug Vyvgart Grows for 17th Consecutive Quarter

08:20 With first-quarter revenue of 1.3 billion dollars, the versatile Vyvgart treatment from Ghent-based biotech company Argenx meets expectations. These are the first figures from newly...

·Belgium
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

De Tijd broke the news in Belgium on Thursday, May 7, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Technology icon

Technology

Belgium icon

Belgium

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal